ResMed stock trades at EUR 195.18 after RBC raises target

Published on 09/30/2026 at 16:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ResMed stock faces a new USD 262.00 target after RBC raised it from USD 244.00 on September 15, 2026. Fiscal 2026 revenue reached USD 5.7 billion, up 8.00 percent year over year.

Schwarzweiß-Reportagefoto eines Patienten mit Atemmaske im Schlaflabor — ResMed Inc. (ISIN US7611521078): dokumentarische Schwarzweiß-Reportage zeigt einen Patienten mit Atemmaske im Schlaflabor, Illustration mit AI erstellt.

ResMed stock trades at EUR 195.18 at Lang & Schwarz on September 30, 2026 at 4:12 p.m. CEST, down 0.66 percent from the prior close of EUR 196.48. The key market question is whether stronger fiscal 2026 growth can offset a cautious analyst consensus.

RBC raises its target

According to MarketBeat on September 15, 2026, Royal Bank of Canada upgraded ResMed to Outperform from Sector Perform and raised its price target from USD 244.00 to USD 262.00. The new target is 34.23 percent above the Lang & Schwarz price, but the comparison uses different currencies and is therefore only a directional analyst reference, not a return calculation.

TradingView reported on September 21, 2026 that ResMed delivered fiscal 2026 revenue of USD 5.7 billion, with earnings per share up 16.00 percent year over year. The same report linked the outlook to sleep-device demand, digital health expansion and capital allocation.

Quarterly growth meets valuation

For the quarter reported on August 6, 2026, ResMed posted adjusted EPS of USD 2.95 against an adjusted consensus estimate of USD 2.89, according to MarketBeat. Quarterly revenue reached USD 1.46 billion and increased 8.60 percent year over year, giving the growth case a concrete operating base.

The counterweight is valuation and analyst dispersion. MarketBeat listed a consensus Hold rating and an average target of USD 241.69, while recent targets ranged from USD 225.00 to USD 267.00 on September 30, 2026. ResMed therefore combines double-digit EPS growth with a market view that is positive on operations but less uniform on upside.

NYSE valuation and stock range

ResMed had a market capitalization of USD 32.1 billion on September 30, 2026. Its NYSE 52-week range was USD 180.27 to USD 284.87, placing the US-listed stock below its yearly high while the euro quotation remained the relevant reference for German investors.

EUR 195.18 in afternoon trading

At Lang & Schwarz, ResMed was trading at EUR 195.18 on September 30, 2026 at 4:12 p.m. CEST, down 0.66 percent versus the Lang & Schwarz prior close of EUR 196.48 on September 29, 2026. The latest quote leaves the RBC target and the fiscal 2026 growth figures as the main measurable reference points for the stock.